A missense variant in human perilipin 2 (PLIN2 Ser251Pro) reduces hepatic steatosis in mice
© 2023 The Author(s)..
Background & Aims: Non-alcoholic fatty liver disease (NAFLD) is characterised by the accumulation of lipid droplets (LDs) within hepatocytes. Perilipin 2 (PLIN2) is the most abundant protein in hepatic LDs and its expression correlates with intracellular lipid accumulation. A recently discovered PLIN2 coding variant, Ser251Pro (rs35568725), was found to promote the accumulation of small LDs in embryonic kidney cells. In this study, we investigate the role of PLIN2-Ser251Pro (PLIN2-Pro251) on hepatic LD metabolism in vivo and research the metabolic phenotypes associated with this variant in humans.
Methods: For our animal model, we used Plin2 knockout mice in which we expressed either human PLIN2-Pro251 (Pro251 mice) or wild-type human PLIN2-Ser251 (Ser251 mice) in a hepatocyte-specific manner. We fed both cohorts a lipogenic high-fat, high-cholesterol, high-fructose diet for 12 weeks.
Results: Pro251 mice were associated with reduced liver triglycerides (TGs) and had lower mRNA expression of fatty acid synthase and diacylglycerol O-acyltransferase-2 compared with Ser251 mice. Moreover, Pro251 mice had a reduction of polyunsaturated fatty acids-TGs and reduced expression of epoxygenase genes. For our human study, we analysed the Penn Medicine BioBank, the Million Veteran Program, and UK Biobank. Across these databases, the minor allele frequency of PLIN2-Pro251 was approximately 5%. There was no association with the clinical diagnosis of NAFLD, however, there was a trend toward reduced liver fat in PLIN2-Pro251 carriers by MRI-spectroscopy in UK Biobank subjects.
Conclusions: In mice lacking endogenous Plin2, expression of human PLIN2-Pro251 attenuated high-fat, high-fructose, high-cholesterol, diet-induced hepatic steatosis compared with human wild-type PLIN2-Ser251. Moreover, Pro251 mice had lower polyunsaturated fatty acids-TGs and epoxygenase genes expression, suggesting less liver oxidative stress. In humans, PLIN2-Pro251 is not associated with NAFLD.
Impact and Implications: Lipid droplet accumulation in hepatocytes is the distinctive characteristic of non-alcoholic fatty liver disease. Perilipin 2 (PLIN2) is the most abundant protein in hepatic lipid droplets; however, little is known on the role of a specific polymorphism PLIN2-Pro251 on hepatic lipid droplet metabolism. PLIN2-Pro251 attenuates liver triglycerides accumulation after a high-fat-high-glucose-diet. PLIN2-Pro251 may be a novel lipid droplet protein target for the treatment of liver steatosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
JHEP reports : innovation in hepatology - 6(2024), 1 vom: 11. Jan., Seite 100902 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Scorletti, Eleonora [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
DGAT2 |
|---|
| Anmerkungen: |
Date Revised 10.02.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.jhepr.2023.100902 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365653144 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365653144 | ||
| 003 | DE-627 | ||
| 005 | 20240210232948.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jhepr.2023.100902 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1287.xml |
| 035 | |a (DE-627)NLM365653144 | ||
| 035 | |a (NLM)38074507 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Scorletti, Eleonora |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A missense variant in human perilipin 2 (PLIN2 Ser251Pro) reduces hepatic steatosis in mice |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 10.02.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 The Author(s). | ||
| 520 | |a Background & Aims: Non-alcoholic fatty liver disease (NAFLD) is characterised by the accumulation of lipid droplets (LDs) within hepatocytes. Perilipin 2 (PLIN2) is the most abundant protein in hepatic LDs and its expression correlates with intracellular lipid accumulation. A recently discovered PLIN2 coding variant, Ser251Pro (rs35568725), was found to promote the accumulation of small LDs in embryonic kidney cells. In this study, we investigate the role of PLIN2-Ser251Pro (PLIN2-Pro251) on hepatic LD metabolism in vivo and research the metabolic phenotypes associated with this variant in humans | ||
| 520 | |a Methods: For our animal model, we used Plin2 knockout mice in which we expressed either human PLIN2-Pro251 (Pro251 mice) or wild-type human PLIN2-Ser251 (Ser251 mice) in a hepatocyte-specific manner. We fed both cohorts a lipogenic high-fat, high-cholesterol, high-fructose diet for 12 weeks | ||
| 520 | |a Results: Pro251 mice were associated with reduced liver triglycerides (TGs) and had lower mRNA expression of fatty acid synthase and diacylglycerol O-acyltransferase-2 compared with Ser251 mice. Moreover, Pro251 mice had a reduction of polyunsaturated fatty acids-TGs and reduced expression of epoxygenase genes. For our human study, we analysed the Penn Medicine BioBank, the Million Veteran Program, and UK Biobank. Across these databases, the minor allele frequency of PLIN2-Pro251 was approximately 5%. There was no association with the clinical diagnosis of NAFLD, however, there was a trend toward reduced liver fat in PLIN2-Pro251 carriers by MRI-spectroscopy in UK Biobank subjects | ||
| 520 | |a Conclusions: In mice lacking endogenous Plin2, expression of human PLIN2-Pro251 attenuated high-fat, high-fructose, high-cholesterol, diet-induced hepatic steatosis compared with human wild-type PLIN2-Ser251. Moreover, Pro251 mice had lower polyunsaturated fatty acids-TGs and epoxygenase genes expression, suggesting less liver oxidative stress. In humans, PLIN2-Pro251 is not associated with NAFLD | ||
| 520 | |a Impact and Implications: Lipid droplet accumulation in hepatocytes is the distinctive characteristic of non-alcoholic fatty liver disease. Perilipin 2 (PLIN2) is the most abundant protein in hepatic lipid droplets; however, little is known on the role of a specific polymorphism PLIN2-Pro251 on hepatic lipid droplet metabolism. PLIN2-Pro251 attenuates liver triglycerides accumulation after a high-fat-high-glucose-diet. PLIN2-Pro251 may be a novel lipid droplet protein target for the treatment of liver steatosis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a DGAT2 | |
| 650 | 4 | |a Lipid droplets | |
| 650 | 4 | |a NAFLD | |
| 650 | 4 | |a Perilipin | |
| 650 | 4 | |a triglycerides | |
| 700 | 1 | |a Saiman, Yedidya |e verfasserin |4 aut | |
| 700 | 1 | |a Jeon, Sookyoung |e verfasserin |4 aut | |
| 700 | 1 | |a Schneider, Carolin V |e verfasserin |4 aut | |
| 700 | 1 | |a Buyco, Delfin G |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Chelsea |e verfasserin |4 aut | |
| 700 | 1 | |a Himes, Blanca E |e verfasserin |4 aut | |
| 700 | 1 | |a Mesaros, Clementina A |e verfasserin |4 aut | |
| 700 | 1 | |a Vujkovic, Marijana |e verfasserin |4 aut | |
| 700 | 1 | |a Creasy, Kate Townsend |e verfasserin |4 aut | |
| 700 | 1 | |a Furth, Emma E |e verfasserin |4 aut | |
| 700 | 1 | |a Billheimer, Jeffrey T |e verfasserin |4 aut | |
| 700 | 1 | |a Hand, Nicholas J |e verfasserin |4 aut | |
| 700 | 1 | |a Kaplan, David E |e verfasserin |4 aut | |
| 700 | 1 | |a Chang, Kyong-Mi |e verfasserin |4 aut | |
| 700 | 1 | |a Tsao, Philip S |e verfasserin |4 aut | |
| 700 | 1 | |a Lynch, Julie A |e verfasserin |4 aut | |
| 700 | 1 | |a Dempsey, Joseph L |e verfasserin |4 aut | |
| 700 | 1 | |a Harkin, Julia |e verfasserin |4 aut | |
| 700 | 1 | |a Bayen, Susovon |e verfasserin |4 aut | |
| 700 | 1 | |a Conlon, Donna |e verfasserin |4 aut | |
| 700 | 1 | |a Guerraty, Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Phillips, Michael C |e verfasserin |4 aut | |
| 700 | 1 | |a Rader, Daniel J |e verfasserin |4 aut | |
| 700 | 1 | |a Carr, Rotonya M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JHEP reports : innovation in hepatology |d 2019 |g 6(2024), 1 vom: 11. Jan., Seite 100902 |w (DE-627)NLM306339021 |x 2589-5559 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2024 |g number:1 |g day:11 |g month:01 |g pages:100902 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jhepr.2023.100902 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2024 |e 1 |b 11 |c 01 |h 100902 | ||